Endpoints News 生物医药· Lei Lei Wu·· 12 天前AI 评分55
FDA 调查诺华 Zolgensma 与癌症风险相关性
FDA launches investigation of Novartis’ Zolgensma after cancer cases
AI 导读
FDA 正在调查诺华的脊髓性肌萎缩基因疗法 Zolgensma 与严重癌症风险的相关性。
正文
The FDA is looking into a “serious risk” of cancer linked to Novartis’ spinal muscular atrophy gene therapy Zolgensma, the agency
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news